Samalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD200 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6542H10086N1702O2102S46 |
| Molar mass | 147687.22 g·mol−1 |
  (what is this?) (verify) | |
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]
Samalizumab was developed by Alexion Pharmaceuticals.
References[edit]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
- ^ "Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |